Schrodinger, Inc. (SDGR): R&D Expense
$173.14M
Year ended 2025-12-31
$168.98M
Trailing 12 months to 2026-06-30
+11.1%
3-year compound annual growth
+21.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $173.14M | -14.2% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $201.78M | +11.0% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $181.77M | +43.8% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $126.37M | +39.0% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $90.90M | +40.5% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $64.69M | +64.2% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $39.40M | n/a | 2022-02-24, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $173.14M | -14.2% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $285.20M | -18.1% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $523.00M | +16.7% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $81.18M | +278.9% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $129.64M | -25.3% |
| Harrow, Inc. (HROW) | 2025-12-31 | $20.94M | +71.2% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $62.36M | +65.6% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $135.97M | -17.0% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $62.07M | +13.0% |
Compare SDGR, ARVN, RCUS, LGND side by side · Screen every company in Pharmaceutical Preparations ↗